Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma

Launched by ZHONGNAN HOSPITAL · Dec 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at two different treatment options for patients with a type of brain cancer called glioblastoma multiforme, specifically those whose tumors have an unmethylated MGMT gene. The researchers want to see if combining two medications, Cisplatin and Temozolomide, is more effective than using Temozolomide alone for these patients. Temozolomide has previously shown benefits for patients with a different type of glioblastoma, but its effect is limited for those with the unmethylated gene.

To join the trial, participants need to be between 18 and 75 years old and have been diagnosed with glioblastoma confirmed by a medical professional. They should be in good health overall, without any significant other illnesses, and must not have any other major cancers. The trial is currently not recruiting participants, but those who qualify can expect to receive treatment and monitoring throughout the study. This research is important as it aims to find better treatment options for patients who currently have limited choices.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 75, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed MGMT gene promoter unmethylation glioblastoma no cerebrospinal fluid and distant metastatic disease. adequate hematologic, hepatic, and renal function
• Exclusion Criteria:
• • younger than 18 years; with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities